Tianjun Zhou

发表

Structure of Human Nicotinamide/Nicotinic Acid Mononucleotide Adenylyltransferase

N. Grishin, A. Osterman, O. Kurnasov, 2002, The Journal of Biological Chemistry.

Crystal structures of E. coli nicotinate mononucleotide adenylyltransferase and its complex with deamido-NAD.

N. Grishin, A. Osterman, O. Kurnasov, 2002, Structure.

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

J. Fletcher, T. Clackson, M. Heinrich, 2014, Clinical Cancer Research.

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2010, Journal of medicinal chemistry.

Crystal structure of the MAP3K TAO2 kinase domain bound by an inhibitor staurosporine.

E. Goldsmith, T. Zhou, Yan Gao, 2006, Acta biochimica et biophysica Sinica.

Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors.

T. Clackson, V. Rivera, T. Zhou, 2013, Journal of medicinal chemistry.

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

T. Clackson, B. Druker, A. Corbin, 2009, Cancer cell.

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

T. Clackson, V. Rivera, T. Zhou, 2011, Chemical biology & drug design.

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

T. Clackson, R. Anjum, V. Rivera, 2016, Clinical Cancer Research.

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.

T. Clackson, R. Anjum, V. Rivera, 2016, Journal of medicinal chemistry.

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2011, Bioorganic & medicinal chemistry letters.

Structural Analysis of DFG‐in and DFG‐out Dual Src‐Abl Inhibitors Sharing a Common Vinyl Purine Template

T. Clackson, T. Zhou, T. Sawyer, 2009, Chemical biology & drug design.

Substrate and docking interactions in serine/threonine protein kinases.

Radha Akella, E. Goldsmith, J. Humphreys, 2007, Chemical reviews.

Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery.

T. Zhou, M. Greenfield, J. Miret, 2016, Journal of medicinal chemistry.

Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants

T. Clackson, V. Rivera, W. Shakespeare, 2015 .

Substrate and Docking Interactions in Serine/Threonine Protein Kinases

Elizabeth J. Goldsmith, Radha Akella, E. Goldsmith, 2008 .

Docking interactions induce exposure of activation loop in the MAP kinase ERK2.

E. Goldsmith, J. Humphreys, T. Zhou, 2006, Structure.

Crystallization of MAP kinases.

E. Goldsmith, T. Zhou, Seung-Jae Lee, 2006, Methods.

Structural studies of MAP Kinase cascade components.

E. Goldsmith, Haixia He, Xiaoshan Min, 2010, Methods in molecular biology.

Crystal structure of the TAO2 kinase domain: activation and specificity of a Ste20p MAP3K.

E. Goldsmith, M. Machius, M. Cobb, 2004, Structure.

Crystal Structure of the T315I Mutant of Abl Kinase

T. Zhou, W. Shakespeare, Sarah D. Lamore, 2007, Chemical biology & drug design.